

TML: CS: BSE/NSE CORR: 2019-20

8th July, 2019

BSE Limited.

P. J. Towers, Dalal Street, Mumbai-400001

National Stock Exchange of India Ltd.

"Exchange Plaza", Bandra - Kurla Complex,

Bandra - East, Mumbai- 400 051

1. Regulation 30 of SEBI (LODR) Regulations, 2015

2. BSE Scrip Code: 530199

3. NSE Scrip Code: THEMISMED

Dear Sir/Madam,

Sub:- Update on Litigation

This is further to our disclosure on the captioned matter made on July 12, 2018.

We, hereby, inform you that the Company had received a letter dated 11th July, 2018 from the Food and Drug Administration (FDA) authorities directing, inter alia, not to manufacture a key product till deciding of the matter. The Company, being aggrieved by the developments, had filed a Writ Petition in the Hon'ble Delhi High Court in this connection and the same was admitted by the Hon'ble Delhi High Court.

However, the Hon'ble Delhi High Court vide its order dated July 5, 2018 has dismissed the Company's petition.

Meanwhile, since the Court has uploaded a copy of the same on its website, the Company is hereby making the disclosure. Also the Company has applied for a certified copy of the order and the same is awaited.

The Company believes it has a strong case and intends to file an appeal against the said order in consultation with its lawyers.

This may be taken as a disclosure under Regulation 30 of the SEBI (LODR) Regulations, 2015.

The Company will keep the Stock Exchange informed of any further developments in this matter.

Thanking you, Yours Faithfully,



Sangameshwar lyer Company Secretary& Compliance Officer

Themis Medicare Limited

• E-mail: themis@themismedicare.com • Website: www.themismedicare.com